Close menu




January 2nd, 2020 | 05:45 CET

NEL ASA, Saturn Oil & Gas, VARTA - which stock will be the top performer in 2020?

  • Investments
Photo credits: pixabay.com

If it runs, it runs! This or something similar is how the demand for the stocks of trend themes can be described. Last year, shares of hydrogen companies were in great demand. Also the interest in energy storage was very high. But what did not work at all was the extraction of energy raw materials in the traditional way. A backlog demand has emerged, which will pay off in 2020 according to experts for investors who are there in time.

time to read: 2 minutes | Author: Mario Hose
ISIN: CA80412L1076 , NO0010081235 , DE000A0TGJ55

Table of contents:


    Hydrogen from Norway

    In 2019, the NEL ASA shares were one of the most frequently discussed hydrogen investment opportunities. The Norwegian company develops plants for the production and distribution of hydrogen. In the age of radical change in mobility, hydrogen is one of the cleanest energy sources of the present. The construction of a hydrogen infrastructure is less complex to set up and would require less behavioural changes by the users than would be the case with battery-powered vehicles.

    There are about 14,000 filling stations in Germany, and it would be sufficient to fill them up with hydrogen, because the filling process is similar to that of conventional gasoline or diesel. This is a clear advantage compared to the installation of several million charging points. However, the widespread introduction of hydrogen must also be politically desired.

    Oil from Canada

    Saturn Oil & Gas from Canada is an oil producer that was created three years ago as part of a takeover by a new management team. The company has since developed into a profitable success story. At the current price level of over USD 60.00, the production of WTI grade oil is highly interesting. Saturn Oil & Gas is one of the highest-margin producers in North America, as the company's production costs of approximately USD 12.00 are relatively low.

    The higher the oil price rises, the more money is left for the management to drive growth. However, the issue of oil production was completely neglected on the stock market last year, even though the industry can produce attractive key figures. Despite profitable sales growth of over 350% in the first nine months of 2019, the Saturn Oil & Gas share was traded at around 50% below the level of the previous year. Reason enough for GBC Research to believe that the share has more than 100% upside potential in 2020 and announced a buy recommendation. Ultimately, crude oil demand is not expected to decline in the coming decades, but rather to continue to rise.

    Batteries from Germany

    VARTA, a German company with a long tradition, is now listed in the MDAX as a manufacturer of microbatteries due to its market positioning. The demand for high-quality microbatteries for hearing aids and headphones is high. The company is able to gain market share, especially in the premium segment, as the energy density of VARTA's batteries is expected to be approximately 30% higher than that of Asian suppliers. The advantage for users is that the service life is much longer and they need to be charged less frequently.

    It is speculated that Apple is also among VARTA's customers, and the giant from Cupertino now has a 60% market share in wireless headphones. However, the market for hearing aids is also growing increasingly, so that the demand for high-quality microbatteries from this segment is also unchecked. The demand for VARTA shares was also boosted by the entry into the field of electric mobility. The company belongs to an industrial consortium and is planning to set up a European battery production facility, which also represents a risk if hydrogen as an energy source in mobility becomes politically accepted.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read